Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 9/10

vs
industry
vs
history
Cash-to-Debt No Debt
LMNX's Cash-to-Debt is ranked higher than
98% of the 180 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.46 vs. LMNX: No Debt )
Ranked among companies with meaningful Cash-to-Debt only.
LMNX' s Cash-to-Debt Range Over the Past 10 Years
Min: 11.48  Med: No Debt Max: No Debt
Current: No Debt
Equity-to-Asset 0.90
LMNX's Equity-to-Asset is ranked higher than
96% of the 177 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 0.59 vs. LMNX: 0.90 )
Ranked among companies with meaningful Equity-to-Asset only.
LMNX' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.77  Med: 0.88 Max: 0.96
Current: 0.9
0.77
0.96
Interest Coverage No Debt
LMNX's Interest Coverage is ranked higher than
98% of the 135 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 42.78 vs. LMNX: No Debt )
Ranked among companies with meaningful Interest Coverage only.
LMNX' s Interest Coverage Range Over the Past 10 Years
Min: 5.66  Med: 77.41 Max: No Debt
Current: No Debt
Piotroski F-Score: 5
Altman Z-Score: 11.69
Beneish M-Score: -2.66
WACC vs ROIC
4.16%
5.39%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 7/10

vs
industry
vs
history
Operating Margin % 7.75
LMNX's Operating Margin % is ranked higher than
59% of the 179 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 5.41 vs. LMNX: 7.75 )
Ranked among companies with meaningful Operating Margin % only.
LMNX' s Operating Margin % Range Over the Past 10 Years
Min: -23.22  Med: 7.85 Max: 15.72
Current: 7.75
-23.22
15.72
Net Margin % 5.10
LMNX's Net Margin % is ranked higher than
56% of the 179 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 3.23 vs. LMNX: 5.10 )
Ranked among companies with meaningful Net Margin % only.
LMNX' s Net Margin % Range Over the Past 10 Years
Min: -3.61  Med: 5.61 Max: 17.2
Current: 5.1
-3.61
17.2
ROE % 3.55
LMNX's ROE % is ranked higher than
51% of the 174 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 3.51 vs. LMNX: 3.55 )
Ranked among companies with meaningful ROE % only.
LMNX' s ROE % Range Over the Past 10 Years
Min: -3.44  Med: 4.22 Max: 13.24
Current: 3.55
-3.44
13.24
ROA % 3.24
LMNX's ROA % is ranked higher than
58% of the 182 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.74 vs. LMNX: 3.24 )
Ranked among companies with meaningful ROA % only.
LMNX' s ROA % Range Over the Past 10 Years
Min: -2.85  Med: 3.76 Max: 11.77
Current: 3.24
-2.85
11.77
ROC (Joel Greenblatt) % 21.39
LMNX's ROC (Joel Greenblatt) % is ranked higher than
70% of the 180 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 9.88 vs. LMNX: 21.39 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
LMNX' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -12.68  Med: 23.21 Max: 40.65
Current: 21.39
-12.68
40.65
3-Year Revenue Growth Rate 7.40
LMNX's 3-Year Revenue Growth Rate is ranked higher than
62% of the 144 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 4.00 vs. LMNX: 7.40 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
LMNX' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: 4.8  Med: 20.15 Max: 194.3
Current: 7.4
4.8
194.3
3-Year EBITDA Growth Rate 13.50
LMNX's 3-Year EBITDA Growth Rate is ranked higher than
72% of the 120 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 5.80 vs. LMNX: 13.50 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
LMNX' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -66.9  Med: 10.3 Max: 45.3
Current: 13.5
-66.9
45.3
3-Year EPS without NRI Growth Rate 23.50
LMNX's 3-Year EPS without NRI Growth Rate is ranked higher than
77% of the 115 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 6.50 vs. LMNX: 23.50 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
LMNX' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -52.7  Med: 8.7 Max: 104.9
Current: 23.5
-52.7
104.9
GuruFocus has detected 2 Warning Signs with Luminex Corp $LMNX.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» LMNX's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q1 2016

LMNX Guru Trades in Q1 2016

Jim Simons 1,007,840 sh (+19.12%)
Paul Tudor Jones 36,086 sh (-17.02%)
Joel Greenblatt 62,983 sh (-69.90%)
» More
Q2 2016

LMNX Guru Trades in Q2 2016

Paul Tudor Jones 46,409 sh (+28.61%)
Jim Simons 1,002,900 sh (-0.49%)
Joel Greenblatt 11,923 sh (-81.07%)
» More
Q3 2016

LMNX Guru Trades in Q3 2016

Jim Simons 1,334,240 sh (+33.04%)
Joel Greenblatt Sold Out
Paul Tudor Jones 22,829 sh (-50.81%)
» More
Q4 2016

LMNX Guru Trades in Q4 2016

Paul Tudor Jones 28,352 sh (+24.19%)
Jim Simons 1,346,340 sh (+0.91%)
» More
» Details

Insider Trades

Latest Guru Trades with LMNX

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Medical Instruments & Equipment » Medical Instruments & Supplies    NAICS: 541711    SIC: 3841
Compare:NAS:IRTC, NAS:ATRI, NAS:NVCR, OTCPK:NNCSF, NAS:OSUR, NAS:ANGO, NAS:ATRC, NAS:ELGX, OTCPK:GMDTF, NAS:MLAB, NAS:LMAT, NAS:STAA, NAS:ATRS, NAS:ENTL, NAS:CFMS, NAS:MMSI, NAS:UTMD, NAS:DSCI, NAS:PLSE, AMEX:TRXC » details
Traded in other countries:LMX.Germany,
Luminex Corp develops, manufactures and sells proprietary biological testing technologies and products with applications throughout the life sciences and diagnostics industries. Its products include MAGPIX, Luminex 100/200, & FLEXMAP 3D.

Luminex Corp was incorporated under the laws of the State of Texas in May 1995, and was reincorporated in the State of Delaware in July 2000. The Company develops, manufactures and sells proprietary biological testing technologies and products with applications throughout the life sciences and diagnostics industries. The Company has two reportable segments; TSP segment and ARP segment. The TSP segment represents the Company's base business and consists of system sales to partners, raw bead sales, royalties, service and support of the technology, and other miscellaneous items and the ARP segment is involved in the development and sale of assays on xMAP technology for use on Luminex's installed base of systems, as well as the sale of automated punching systems. The Company also develops and manufactures the proprietary xMAP laboratory instrumentation and the proprietary xMAP microspheres and sells them. The ARP segment is mainly involved in the development and sale of assays utilizing xMAP technology on its installed base of systems. The ARP segment is mainly focused on multiplexed applications for the human molecular clinical diagnostics market. The Company's diagnostic market competitors include Abbott Laboratories, Beckman Coulter, Inc., Celera Corporation, Cepheid, Johnson & Johnson, Roche Diagnostics, Siemens Medical, and Hologic, Inc. It currently owns 281 issued patents, including 110 issued patents in the United States. The Company's trademark includes Luminex, xMAP, xTAG, Luminex 100/200 MicroPlex, MAGPIX, MagPlex, SeroMAP, xPONENT, FlexmiR, NeoPlex4, LumAvidin Et cetera. The Company is subject to federal, state and local laws and regulations relating to the protection of human health and the environment.

Ratios

vs
industry
vs
history
PE Ratio 58.44
LMNX's PE Ratio is ranked lower than
82% of the 118 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 30.87 vs. LMNX: 58.44 )
Ranked among companies with meaningful PE Ratio only.
LMNX' s PE Ratio Range Over the Past 10 Years
Min: 16.42  Med: 62.16 Max: 603.33
Current: 58.44
16.42
603.33
Forward PE Ratio 39.68
LMNX's Forward PE Ratio is ranked lower than
85% of the 40 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 23.15 vs. LMNX: 39.68 )
Ranked among companies with meaningful Forward PE Ratio only.
N/A
PE Ratio without NRI 58.44
LMNX's PE Ratio without NRI is ranked lower than
83% of the 115 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 30.49 vs. LMNX: 58.44 )
Ranked among companies with meaningful PE Ratio without NRI only.
LMNX' s PE Ratio without NRI Range Over the Past 10 Years
Min: 16.42  Med: 62.16 Max: 603.33
Current: 58.44
16.42
603.33
Price-to-Owner-Earnings 35.42
LMNX's Price-to-Owner-Earnings is ranked lower than
62% of the 82 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 27.26 vs. LMNX: 35.42 )
Ranked among companies with meaningful Price-to-Owner-Earnings only.
LMNX' s Price-to-Owner-Earnings Range Over the Past 10 Years
Min: 21.73  Med: 54.2 Max: 882
Current: 35.42
21.73
882
PB Ratio 2.02
LMNX's PB Ratio is ranked higher than
68% of the 188 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 3.45 vs. LMNX: 2.02 )
Ranked among companies with meaningful PB Ratio only.
LMNX' s PB Ratio Range Over the Past 10 Years
Min: 1.96  Med: 3.21 Max: 12.31
Current: 2.02
1.96
12.31
PS Ratio 2.96
LMNX's PS Ratio is ranked higher than
51% of the 190 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.96 vs. LMNX: 2.96 )
Ranked among companies with meaningful PS Ratio only.
LMNX' s PS Ratio Range Over the Past 10 Years
Min: 2.87  Med: 5.01 Max: 12.94
Current: 2.96
2.87
12.94
Price-to-Free-Cash-Flow 22.87
LMNX's Price-to-Free-Cash-Flow is ranked higher than
72% of the 78 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 30.37 vs. LMNX: 22.87 )
Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
LMNX' s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 19.41  Med: 57.09 Max: 430.24
Current: 22.87
19.41
430.24
Price-to-Operating-Cash-Flow 16.55
LMNX's Price-to-Operating-Cash-Flow is ranked higher than
60% of the 101 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 21.55 vs. LMNX: 16.55 )
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
LMNX' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 12.21  Med: 29.97 Max: 270
Current: 16.55
12.21
270
EV-to-EBIT 34.39
LMNX's EV-to-EBIT is ranked lower than
69% of the 118 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 24.36 vs. LMNX: 34.39 )
Ranked among companies with meaningful EV-to-EBIT only.
LMNX' s EV-to-EBIT Range Over the Past 10 Years
Min: -999.3  Med: 32.95 Max: 632.6
Current: 34.39
-999.3
632.6
EV-to-EBITDA 17.56
LMNX's EV-to-EBITDA is ranked higher than
53% of the 129 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 17.65 vs. LMNX: 17.56 )
Ranked among companies with meaningful EV-to-EBITDA only.
LMNX' s EV-to-EBITDA Range Over the Past 10 Years
Min: -105217.5  Med: 24.95 Max: 4060.3
Current: 17.56
-105217.5
4060.3
PEG Ratio 10.41
LMNX's PEG Ratio is ranked lower than
93% of the 56 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 3.03 vs. LMNX: 10.41 )
Ranked among companies with meaningful PEG Ratio only.
LMNX' s PEG Ratio Range Over the Past 10 Years
Min: 1.02  Med: 2.08 Max: 10.41
Current: 10.41
1.02
10.41
Shiller PE Ratio 50.49
LMNX's Shiller PE Ratio is ranked lower than
55% of the 47 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 41.26 vs. LMNX: 50.49 )
Ranked among companies with meaningful Shiller PE Ratio only.
LMNX' s Shiller PE Ratio Range Over the Past 10 Years
Min: 48.58  Med: 105.42 Max: 1224.5
Current: 50.49
48.58
1224.5
Current Ratio 4.32
LMNX's Current Ratio is ranked higher than
77% of the 176 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.39 vs. LMNX: 4.32 )
Ranked among companies with meaningful Current Ratio only.
LMNX' s Current Ratio Range Over the Past 10 Years
Min: 4.25  Med: 7.45 Max: 19.82
Current: 4.32
4.25
19.82
Quick Ratio 3.31
LMNX's Quick Ratio is ranked higher than
76% of the 176 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.62 vs. LMNX: 3.31 )
Ranked among companies with meaningful Quick Ratio only.
LMNX' s Quick Ratio Range Over the Past 10 Years
Min: 3.31  Med: 6.43 Max: 19.23
Current: 3.31
3.31
19.23
Days Inventory 149.39
LMNX's Days Inventory is ranked lower than
64% of the 168 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 123.69 vs. LMNX: 149.39 )
Ranked among companies with meaningful Days Inventory only.
LMNX' s Days Inventory Range Over the Past 10 Years
Min: 69.92  Med: 155.77 Max: 182.42
Current: 149.39
69.92
182.42
Days Sales Outstanding 43.65
LMNX's Days Sales Outstanding is ranked higher than
86% of the 146 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 63.60 vs. LMNX: 43.65 )
Ranked among companies with meaningful Days Sales Outstanding only.
LMNX' s Days Sales Outstanding Range Over the Past 10 Years
Min: 38.52  Med: 49.25 Max: 66.89
Current: 43.65
38.52
66.89
Days Payable 49.25
LMNX's Days Payable is ranked higher than
50% of the 139 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 49.38 vs. LMNX: 49.25 )
Ranked among companies with meaningful Days Payable only.
LMNX' s Days Payable Range Over the Past 10 Years
Min: 36.85  Med: 52.92 Max: 78.2
Current: 49.25
36.85
78.2

Buy Back

vs
industry
vs
history
Forward Dividend Yield % 1.29
LMNX's Forward Dividend Yield % is ranked lower than
99.99% of the 138 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.37 vs. LMNX: 1.29 )
Ranked among companies with meaningful Forward Dividend Yield % only.
N/A
3-Year Average Share Buyback Ratio -1.90
LMNX's 3-Year Average Share Buyback Ratio is ranked higher than
54% of the 117 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: -2.80 vs. LMNX: -1.90 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
LMNX' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -30.8  Med: -2.55 Max: 0.4
Current: -1.9
-30.8
0.4

Valuation & Return

vs
industry
vs
history
Price-to-Net-Cash 17.48
LMNX's Price-to-Net-Cash is ranked lower than
55% of the 51 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 13.50 vs. LMNX: 17.48 )
Ranked among companies with meaningful Price-to-Net-Cash only.
LMNX' s Price-to-Net-Cash Range Over the Past 10 Years
Min: 3.74  Med: 11.84 Max: 41.64
Current: 17.48
3.74
41.64
Price-to-Net-Current-Asset-Value 6.43
LMNX's Price-to-Net-Current-Asset-Value is ranked higher than
54% of the 114 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 7.51 vs. LMNX: 6.43 )
Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only.
LMNX' s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 2.85  Med: 7.17 Max: 17.85
Current: 6.43
2.85
17.85
Price-to-Tangible-Book 3.49
LMNX's Price-to-Tangible-Book is ranked higher than
65% of the 159 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 4.64 vs. LMNX: 3.49 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
LMNX' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 2.66  Med: 5.03 Max: 12.67
Current: 3.49
2.66
12.67
Price-to-Intrinsic-Value-Projected-FCF 1.34
LMNX's Price-to-Intrinsic-Value-Projected-FCF is ranked higher than
80% of the 80 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.03 vs. LMNX: 1.34 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
LMNX' s Price-to-Intrinsic-Value-Projected-FCF Range Over the Past 10 Years
Min: 1.33  Med: 2.6 Max: 11.2
Current: 1.34
1.33
11.2
Price-to-Intrinsic-Value-DCF (Earnings Based) 5.47
LMNX's Price-to-Intrinsic-Value-DCF (Earnings Based) is ranked lower than
95% of the 20 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.97 vs. LMNX: 5.47 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-DCF (Earnings Based) only.
N/A
Price-to-Median-PS-Value 0.59
LMNX's Price-to-Median-PS-Value is ranked higher than
88% of the 164 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.10 vs. LMNX: 0.59 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
LMNX' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.59  Med: 1.49 Max: 13.43
Current: 0.59
0.59
13.43
Price-to-Peter-Lynch-Fair-Value 5.30
LMNX's Price-to-Peter-Lynch-Fair-Value is ranked lower than
83% of the 35 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.80 vs. LMNX: 5.30 )
Ranked among companies with meaningful Price-to-Peter-Lynch-Fair-Value only.
LMNX' s Price-to-Peter-Lynch-Fair-Value Range Over the Past 10 Years
Min: 1.24  Med: 3.85 Max: 13.1
Current: 5.3
1.24
13.1
Price-to-Graham-Number 3.01
LMNX's Price-to-Graham-Number is ranked lower than
56% of the 89 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.77 vs. LMNX: 3.01 )
Ranked among companies with meaningful Price-to-Graham-Number only.
LMNX' s Price-to-Graham-Number Range Over the Past 10 Years
Min: 1.81  Med: 3.56 Max: 9.14
Current: 3.01
1.81
9.14
Earnings Yield (Greenblatt) % 2.89
LMNX's Earnings Yield (Greenblatt) % is ranked higher than
59% of the 194 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.80 vs. LMNX: 2.89 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
LMNX' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: 0.2  Med: 2.6 Max: 6.7
Current: 2.89
0.2
6.7
Forward Rate of Return (Yacktman) % 14.12
LMNX's Forward Rate of Return (Yacktman) % is ranked higher than
69% of the 87 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 8.86 vs. LMNX: 14.12 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) % only.
LMNX' s Forward Rate of Return (Yacktman) % Range Over the Past 10 Years
Min: -1.8  Med: 1 Max: 29
Current: 14.12
-1.8
29

More Statistics

Revenue (TTM) (Mil) $270.6
EPS (TTM) $ 0.32
Beta0.23
Short Percentage of Float7.37%
52-Week Range $17.64 - 23.75
Shares Outstanding (Mil)43.58

Analyst Estimate

Dec17 Dec18 Dec19
Revenue (Mil $) 300 293 291
EPS ($) 0.47 0.73 0.72
EPS without NRI ($) 0.47 0.73 0.72
EPS Growth Rate
(Future 3Y To 5Y Estimate)
N/A
Dividends per Share ($)
» More Articles for LMNX

Headlines

Articles On GuruFocus.com
BSX and ABMD Highlight Increased Insider Buying in the Medical Technology Sector May 14 2013 
Luminex Corp. (LMNX) CEO Patrick J Balthrop buys 7,000 Shares Mar 02 2010 
Luminex Corp. (LMNX) CEO Patrick J Balthrop buys 7,000 Shares Nov 16 2009 

More From Other Websites
LUMINEX CORP Files SEC form 10-K, Annual Report Feb 24 2017
LUMINEX CORP Files SEC form 8-K, Other Events, Financial Statements and Exhibits Feb 21 2017
Luminex Corporation Announces Initiation of Cash Dividend Feb 21 2017
Luminex Corp. :LMNX-US: Earnings Analysis: Q4, 2016 By the Numbers : February 9, 2017 Feb 09 2017
Luminex Corp. :LMNX-US: Earnings Analysis: 2016 By the Numbers : February 8, 2017 Feb 08 2017
Luminex (LMNX) Posts Loss in Q4, Revenues Miss Estimates Feb 07 2017
Edited Transcript of LMNX earnings conference call or presentation 6-Feb-17 9:30pm GMT Feb 07 2017
Luminex reports 4Q loss Feb 06 2017
Luminex reports 4Q loss Feb 06 2017
Luminex Corp Earnings Call scheduled for 4:30 pm ET today Feb 06 2017
LUMINEX CORP Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements... Feb 06 2017
Luminex Corporation Reports Fourth Quarter And Full Year 2016 Results Feb 06 2017
Q4 2016 Luminex Corp Earnings Release - After Market Close Feb 06 2017
Should You Sell Luminex (LMNX) Before Earnings? Feb 03 2017
Medical Product Stocks' Earnings on Feb 6: HAE, PAHC & More Feb 03 2017
Coverage initiated on Luminex by Deutsche Bank Jan 18 2017
Luminex Corp. breached its 50 day moving average in a Bearish Manner : LMNX-US : January 18, 2017 Jan 18 2017
Luminex Projects Strong Q4 Revenues, Issues 2017 Guidance Jan 11 2017
A primer for one of nation's largest health care conferences, Austin companies included Jan 09 2017
LUMINEX CORP Files SEC form 8-K, Results of Operations and Financial Condition, Regulation FD... Jan 09 2017

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)